Naturally-occurring substance proves effective against deadly skin cancer in test tube and mice studies

Apr. 10, 2013 ? For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin cancer.

"We identified gossypin as a novel agent with dual inhibitory activity towards two common mutations that are the ideal targets for melanoma treatment," said Texas Biomed's Hareesh Nair, Ph.D.

At the moment, there is no single therapeutic agent or combination regimen available to treat all melanomas, of which about 76,000 new cases are diagnosed annually, according to the American Cancer Society.

"Our results indicate that gossypin may have great therapeutic potential as a dual inhibitor of mutations called BRAFV600E kinase and CDK4, which occur in the vast majority of melanoma patients. They open a new avenue for the generation of a novel class of compounds for the treatment of melanoma," Nair added.

His report, appearing in the March 29, 2013 issue of the journal Molecular Cancer Therapeutics, was funded by the Texas Biomedical Forum and the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation.

Nair and his colleagues found that gossypin inhibited human melanoma cell proliferation, in vitro, in melanoma cell lines that harbor the two mutations. Gossypin stunted activities of the mutated genes, possibly through direct binding with them. It also inhibited the growth of various human melanoma cells. In addition, gossypin treatment for 10 days of human melanoma cell tumors with the mutations transplanted into mice reduced tumor volume and increased survival rate.

Further studies are planned by Nair's team to understand how the body absorbs gossypin and how it is metabolized. This idea has been discussed with the Cancer Therapy & Research Center at the UT Health Science Center San Antonio's Deva Mahalingam, M.D, Ph.D., who is interested in testing gossypin in melanoma patients.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by Texas Biomedical Research Institute.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Journal Reference:

1. S. Bhaskaran, K. V. Dileep, S. S. Deepa, C. Sadasivan, M. Klausner, N. K. Krishnegowda, R. R. Tekmal, J. L. VandeBerg, H. B. Nair. Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma. Molecular Cancer Therapeutics, 2013; 12 (4): 361 DOI: 10.1158/1535-7163.MCT-12-0965

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/most_popular/~3/JWTEwfgcQAg/130410154627.htm

lakers trade ann arbor news nick young elizabeth smart south dakota state long beach state beasley